US OptionsDetailed Quotes
BEAM241220P70000
- 46.00
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
46.00Open46.00Pre Close0 Volume0 Open Interest70.00Strike Price0.00Turnover0.00%IV17.27%PremiumDec 20, 2024Expiry Date40.99Intrinsic Value100Multiplier-1DDays to Expiry5.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.69Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Beam Therapeutics Stock Discussion
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics (NASDAQ: BEAM) presented new data for its ESCAPE conditioning platform at the ASH Annual Meeting. The data demonstrated successful proof-of-concept in non-human primates (NHPs) for a non-genotoxic conditionin...
Sells🔴\\ $Zoom Communications (ZM.US)$ $Trimble (TRMB.US)$ $Twist Bioscience (TWST.US)$ $UiPath (PATH.US)$
• Editing Genes | $CRISPR Therapeutics (CRSP.US)$ , $Intellia Therapeutics (NTLA.US)$ , $Beam Therapeutics (BEAM.US)$ , $Verve Therapeutics (VERV.US)$ , $Editas Medicine (EDIT.US)$
• Creating Therapies | $Prime Medicine (PRME.US)$ , $Sana Biotechnology (SANA.US)$
• Building DNA | $Twist Bioscience (TWST.US)$ , $Ginkgo Bioworks (DNA.US)$ , $Pacific Biosciences of California (PACB.US)$ , $Illumina (ILMN.US)$
• Dis...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
"A turning point in medicine"
Scientists have made significant progress in treating thousands of illnesses over the years, but finding cures for rare and deadly diseases remains a significant challenge. While treatments for inherited conditions like sickle cell...
Dow Jones· 4 mins ago
No comment yet